<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36017003</PMID><DateRevised><Year>2023</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>RAGE pathway activation and function in chronic kidney disease and COVID-19.</ArticleTitle><Pagination><StartPage>970423</StartPage><MedlinePgn>970423</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">970423</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2022.970423</ELocationID><Abstract><AbstractText>The multi-ligand receptor for advanced glycation end-products (RAGE) and its ligands are contributing factors in autoimmunity, cancers, and infectious disease. RAGE activation is increased in chronic kidney disease (CKD) and coronavirus disease 2019 (COVID-19). CKD may increase the risk of COVID-19 severity and may also develop in the form of long COVID. RAGE is expressed in essentially all kidney cell types. Increased production of RAGE isoforms and RAGE ligands during CKD and COVID-19 promotes RAGE activity. The downstream effects include cellular dysfunction, tissue injury, fibrosis, and inflammation, which in turn contribute to a decline in kidney function, hypertension, thrombotic disorders, and cognitive impairment. In this review, we discuss the forms and mechanisms of RAGE and RAGE ligands in the kidney and COVID-19. Because various small molecules antagonize RAGE activity in animal models, targeting RAGE, its co-receptors, or its ligands may offer novel therapeutic approaches to slowing or halting progressive kidney disease, for which current therapies are often inadequate.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Curran and Kopp.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Curran</LastName><ForeName>Colleen S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Critical Care Medicine Department, Clinical Center, National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopp</LastName><ForeName>Jeffrey B</ForeName><Initials>JB</Initials><AffiliationInfo><Affiliation>Kidney Disease Section, NIDDK (National Institute of Diabetes and Digestive and Kidney Diseases), National Institutes of Health, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">High-mobility group box 1</Keyword><Keyword MajorTopicYN="N">S100A8</Keyword><Keyword MajorTopicYN="N">S100A9</Keyword><Keyword MajorTopicYN="N">complement C1q</Keyword><Keyword MajorTopicYN="N">lysophosphatidic acid</Keyword><Keyword MajorTopicYN="N">macrophage antigen 1</Keyword><Keyword MajorTopicYN="N">receptor for advanced glycation end-products</Keyword><Keyword MajorTopicYN="N">urokinase-type plasminogen activator receptor</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>7</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>2</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36017003</ArticleId><ArticleId IdType="pmc">PMC9395689</ArticleId><ArticleId IdType="doi">10.3389/fmed.2022.970423</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Curran CS, Kopp JB. Aryl hydrocarbon receptor mechanisms affecting chronic kidney disease. Front Pharmacol. (2022) 13:782199. 10.3389/fphar.2022.782199</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.782199</ArticleId><ArticleId IdType="pmc">PMC8882872</ArticleId><ArticleId IdType="pubmed">35237156</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver SA, Beaubien-Souligny W, Shah PS, Harel S, Blum D, Kishibe T, et al. . The prevalence of acute kidney injury in patients hospitalized with COVID-19 infection: a systematic review and meta-analysis. Kidney Med. (2021) 3:83&#x2013;98 e81. 10.1016/j.xkme.2020.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xkme.2020.11.008</ArticleId><ArticleId IdType="pmc">PMC7723763</ArticleId><ArticleId IdType="pubmed">33319190</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu EL, Janse RJ, de Jong Y, van der Endt VHW, Milders J, van der Willik EM, et al. . Acute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis. Clin Kidney J. (2020) 13:550&#x2013;563. 10.1093/ckj/sfaa160</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ckj/sfaa160</ArticleId><ArticleId IdType="pmc">PMC7467593</ArticleId><ArticleId IdType="pubmed">32897278</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu CM, Gupta S, Tighiouart H, Goyal N, Faugno AJ, Tariq A, et al. . Kidney recovery and death in critically ill patients with COVID-19-associated acute kidney injury treated with dialysis: the STOP-COVID cohort study. Am J Kidney Dis. (2022) 79:404&#x2013;16 e401. 10.1053/j.ajkd.2021.11.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2021.11.004</ArticleId><ArticleId IdType="pmc">PMC8641974</ArticleId><ArticleId IdType="pubmed">34871701</ArticleId></ArticleIdList></Reference><Reference><Citation>Fisher M, Neugarten J, Bellin E, Yunes M, Stahl L, Johns TS, et al. . AKI in hospitalized patients with and without COVID-19: a comparison study. J Am Soc Nephrol. (2020) 31:2145&#x2013;57. 10.1681/ASN.2020040509</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2020040509</ArticleId><ArticleId IdType="pmc">PMC7461660</ArticleId><ArticleId IdType="pubmed">32669322</ArticleId></ArticleIdList></Reference><Reference><Citation>Dereli N, Babayigit M, Mentes O, Koc F, Ari O, Dogan E, et al. . Are we aware of COVID-19-related acute kidney injury in intensive care units? Eur Rev Med Pharmacol Sci. (2022) 26:1753&#x2013;60. 10.26355/eurrev_202203_28245</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202203_28245</ArticleId><ArticleId IdType="pubmed">35302225</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B, Xie Y, Xu E, Al-Aly Z. Kidney outcomes in long COVID. J Am Soc Nephrol. (2021) 32:2851&#x2013;62. 10.1681/ASN.2021060734</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2021060734</ArticleId><ArticleId IdType="pmc">PMC8806085</ArticleId><ArticleId IdType="pubmed">34470828</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy VP, Beyaz A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov Today. (2006) 11:646&#x2013;54. 10.1016/j.drudis.2006.05.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2006.05.016</ArticleId><ArticleId IdType="pubmed">16793534</ArticleId></ArticleIdList></Reference><Reference><Citation>Linden E, Cai W, He JC, Xue C, Li Z, Winston J, et al. . Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol. (2008) 3:691&#x2013;8. 10.2215/CJN.04291007</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.04291007</ArticleId><ArticleId IdType="pmc">PMC2386710</ArticleId><ArticleId IdType="pubmed">18256374</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugaya K, Fukagawa T, Matsumoto K, Mita K, Takahashi E, Ando A, et al. . Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics. (1994) 23:408&#x2013;19. 10.1006/geno.1994.1517</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/geno.1994.1517</ArticleId><ArticleId IdType="pubmed">7835890</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Diez R, Rastrojo A, Villate O, Aguado B. Complex tissue-specific patterns and distribution of multiple RAGE splice variants in different mammals. Genome Biol Evol. (2013) 5:2420&#x2013;35. 10.1093/gbe/evt188</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gbe/evt188</ArticleId><ArticleId IdType="pmc">PMC3879976</ArticleId><ArticleId IdType="pubmed">24273313</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparvero LJ, Asafu-Adjei D, Kang R, Tang D, Amin N, Im J, et al. . RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. (2009) 7:17. 10.1186/1479-5876-7-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-7-17</ArticleId><ArticleId IdType="pmc">PMC2666642</ArticleId><ArticleId IdType="pubmed">19292913</ArticleId></ArticleIdList></Reference><Reference><Citation>Villegas-Rodriguez ME, Uribarri J, Solorio-Meza SE, Fajardo-Araujo ME, Cai W, Torres-Graciano S, et al. . The AGE-RAGE axis and its relationship to markers of cardiovascular disease in newly diagnosed diabetic patients. PLoS ONE. (2016) 11:e0159175. 10.1371/journal.pone.0159175</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0159175</ArticleId><ArticleId IdType="pmc">PMC4951143</ArticleId><ArticleId IdType="pubmed">27434539</ArticleId></ArticleIdList></Reference><Reference><Citation>Diekmann F, Chouvarine P, Sallmon H, Meyer-Kobbe L, Kieslich M, Plouffe BD, et al. . Soluble Receptor for Advanced Glycation End Products (sRAGE) is a sensitive biomarker in human pulmonary arterial hypertension. Int J Mol Sci. (2021) 22:8591. 10.3390/ijms22168591</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168591</ArticleId><ArticleId IdType="pmc">PMC8395319</ArticleId><ArticleId IdType="pubmed">34445297</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak A, Przywara-Chowaniec B, Damasiewicz-Bodzek A, Blachut D, Nowalany-Kozielska E, Tyrpien-Golder K. Advanced Glycation End-Products (AGEs) and Their Soluble Receptor (sRAGE) in women suffering from Systemic Lupus Erythematosus (SLE). Cells. (2021) 10:3523. 10.3390/cells10123523</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10123523</ArticleId><ArticleId IdType="pmc">PMC8700453</ArticleId><ArticleId IdType="pubmed">34944030</ArticleId></ArticleIdList></Reference><Reference><Citation>Page TH, Chiappo D, Brunini F, Garnica J, Blackburn J, Dudhiya F, et al. . Danger-associated molecular pattern molecules and the receptor for advanced glycation end products enhance ANCA-induced responses. Rheumatology. (2022) 61:834&#x2013;45. 10.1093/rheumatology/keab413</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab413</ArticleId><ArticleId IdType="pmc">PMC8824420</ArticleId><ArticleId IdType="pubmed">33974049</ArticleId></ArticleIdList></Reference><Reference><Citation>Park EY, Seo MJ, Park JH. Effects of specific genes activating RAGE on polycystic kidney disease. Am J Nephrol. (2010) 32:169&#x2013;78. 10.1159/000315859</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000315859</ArticleId><ArticleId IdType="pubmed">20606421</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue J, Manigrasso M, Scalabrin M, Rai V, Reverdatto S, Burz DS, et al. . Change in the molecular dimension of a RAGE-ligand complex triggers RAGE signaling. Structure. (2016) 24:1509&#x2013;22. 10.1016/j.str.2016.06.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2016.06.021</ArticleId><ArticleId IdType="pmc">PMC5014727</ArticleId><ArticleId IdType="pubmed">27524199</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlden S, Georas SN. The autotaxin-LPA axis emerges as a novel regulator of lymphocyte homing and inflammation. J Immunol. (2014) 192:851&#x2013;7. 10.4049/jimmunol.1302831</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1302831</ArticleId><ArticleId IdType="pmc">PMC3905607</ArticleId><ArticleId IdType="pubmed">24443508</ArticleId></ArticleIdList></Reference><Reference><Citation>Petry F, Botto M, Holtappels R, Walport MJ, Loos M. Reconstitution of the complement function in C1q-deficient (C1qa-/-) mice with wild-type bone marrow cells. J Immunol. (2001) 167:4033&#x2013;7. 10.4049/jimmunol.167.7.4033</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.167.7.4033</ArticleId><ArticleId IdType="pubmed">11564823</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma W, Rai V, Hudson BI, Song F, Schmidt AM, Barile GR. RAGE binds C1q and enhances C1q-mediated phagocytosis. Cell Immunol. (2012) 274:72&#x2013;82. 10.1016/j.cellimm.2012.02.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellimm.2012.02.001</ArticleId><ArticleId IdType="pubmed">22386596</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S, Liu Z, Xu Z, Liu J, Zhang J. High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies. J Hematol Oncol. (2020) 13:91. 10.1186/s13045-020-00920-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13045-020-00920-3</ArticleId><ArticleId IdType="pmc">PMC7359022</ArticleId><ArticleId IdType="pubmed">32660524</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Song R, Wang Z, Jing Z, Wang S, Ma J. S100A8/A9 in Inflammation. Front Immunol. (2018) 9:1298. 10.3389/fimmu.2018.01298</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01298</ArticleId><ArticleId IdType="pmc">PMC6004386</ArticleId><ArticleId IdType="pubmed">29942307</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen GF, Xu TH, Yan Y, Zhou YR, Jiang Y, Melcher K, et al. . Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin. (2017) 38:1205&#x2013;35. 10.1038/aps.2017.28</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/aps.2017.28</ArticleId><ArticleId IdType="pmc">PMC5589967</ArticleId><ArticleId IdType="pubmed">28713158</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasparitsch M, Arndt AK, Pawlitschek F, Oberle S, Keller U, Kasper M, et al. . RAGE-mediated interstitial fibrosis in neonatal obstructive nephropathy is independent of NF-kappaB activation. Kidney Int. (2013) 84:911&#x2013;9. 10.1038/ki.2013.171</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2013.171</ArticleId><ArticleId IdType="pubmed">23677242</ArticleId></ArticleIdList></Reference><Reference><Citation>Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol. (2013) 94:55&#x2013;68. 10.1189/jlb.1012519</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1012519</ArticleId><ArticleId IdType="pubmed">23543766</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JH, Huang XR, Zhu HJ, Oldfield M, Cooper M, Truong LD, et al. . Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. FASEB J. (2004) 18:176&#x2013;8. 10.1096/fj.02-1117fje</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.02-1117fje</ArticleId><ArticleId IdType="pubmed">12709399</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi M, Yang S, Zhu X, Sun D, Sun D, Jiang X, et al. . The RAGE/STAT5/autophagy axis regulates senescence in mesangial cells. Cell Signal. (2019) 62:109334. 10.1016/j.cellsig.2019.05.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cellsig.2019.05.019</ArticleId><ArticleId IdType="pubmed">31158467</ArticleId></ArticleIdList></Reference><Reference><Citation>Son M, Chung WJ, Oh S, Ahn H, Choi CH, Hong S, et al. . Age dependent accumulation patterns of advanced glycation end product receptor (RAGE) ligands and binding intensities between RAGE and its ligands differ in the liver, kidney, skeletal muscle. Immun Ageing. (2017) 14:12. 10.1186/s12979-017-0095-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-017-0095-2</ArticleId><ArticleId IdType="pmc">PMC5460364</ArticleId><ArticleId IdType="pubmed">28592983</ArticleId></ArticleIdList></Reference><Reference><Citation>Basta G, Leonardis D, Mallamaci F, Cutrupi S, Pizzini P, Gaetano L, et al. . Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int. (2010) 77:225&#x2013;31. 10.1038/ki.2009.419</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2009.419</ArticleId><ArticleId IdType="pubmed">19924100</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonardis D, Basta G, Mallamaci F, Cutrupi S, Pizzini P, Tripepi R, et al. . Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr Metab Cardiovasc Dis. (2012) 22:748&#x2013;55. 10.1016/j.numecd.2010.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.numecd.2010.11.008</ArticleId><ArticleId IdType="pubmed">21470837</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalousova M, Hodkova M, Kazderova M, Fialova J, Tesar V, Dusilova-Sulkova S, et al. . Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis. (2006) 47:406&#x2013;11. 10.1053/j.ajkd.2005.12.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2005.12.028</ArticleId><ArticleId IdType="pubmed">16490618</ArticleId></ArticleIdList></Reference><Reference><Citation>Nusair MB, Rajpurohit N, Alpert MA. Chronic inflammation and coronary atherosclerosis in patients with end-stage renal disease. Cardiorenal Med. (2012) 2:117&#x2013;24. 10.1159/000337082</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000337082</ArticleId><ArticleId IdType="pmc">PMC3376340</ArticleId><ArticleId IdType="pubmed">22851960</ArticleId></ArticleIdList></Reference><Reference><Citation>Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y, et al. . RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. (2003) 162:1123&#x2013;37. 10.1016/S0002-9440(10)63909-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63909-0</ArticleId><ArticleId IdType="pmc">PMC1851245</ArticleId><ArticleId IdType="pubmed">12651605</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishad R, Meshram P, Singh AK, Reddy GB, Pasupulati AK. Activation of Notch1 signaling in podocytes by glucose-derived AGEs contributes to proteinuria. BMJ Open Diabetes Res Care. (2020) 8:e001203. 10.1136/bmjdrc-2020-001203</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2020-001203</ArticleId><ArticleId IdType="pmc">PMC7326296</ArticleId><ArticleId IdType="pubmed">32601154</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasagni L, Ballerini L, Angelotti ML, Parente E, Sagrinati C, Mazzinghi B, et al. . Notch activation differentially regulates renal progenitors proliferation and differentiation toward the podocyte lineage in glomerular disorders. Stem Cells. (2010) 28:1674&#x2013;85. 10.1002/stem.492</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.492</ArticleId><ArticleId IdType="pmc">PMC2996085</ArticleId><ArticleId IdType="pubmed">20680961</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng HT, Miner JH, Lin M, Tansey MG, Roth K, Kopan R. Gamma-secretase activity is dispensable for mesenchyme-to-epithelium transition but required for podocyte and proximal tubule formation in developing mouse kidney. Development. (2003) 130:5031&#x2013;42. 10.1242/dev.00697</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.00697</ArticleId><ArticleId IdType="pubmed">12952904</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao M, Wang X, Wang X, Zhang T, Chi Y, Gao F. The Notch pathway mediates the angiotensin II-induced synthesis of extracellular matrix components in podocytes. Int J Mol Med. (2015) 36:294&#x2013;300. 10.3892/ijmm.2015.2193</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm.2015.2193</ArticleId><ArticleId IdType="pubmed">25902289</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruster C, Bondeva T, Franke S, Tanaka N, Yamamoto H, Wolf G. Angiotensin II upregulates RAGE expression on podocytes: role of AT2 receptors. Am J Nephrol. (2009) 29:538&#x2013;50. 10.1159/000191467</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000191467</ArticleId><ArticleId IdType="pubmed">19129693</ArticleId></ArticleIdList></Reference><Reference><Citation>Pickering RJ, Tikellis C, Rosado CJ, Tsorotes D, Dimitropoulos A, Smith M, et al. . Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. J Clin Invest. (2019) 129:406&#x2013;21. 10.1172/JCI99987</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99987</ArticleId><ArticleId IdType="pmc">PMC6307942</ArticleId><ArticleId IdType="pubmed">30530993</ArticleId></ArticleIdList></Reference><Reference><Citation>Manigrasso MB, Friedman RA, Ramasamy R, D'Agati V, Schmidt AM. Deletion of the formin Diaph1 protects from structural and functional abnormalities in the murine diabetic kidney. Am J Physiol Renal Physiol. (2018) 315:F1601&#x2013;12. 10.1152/ajprenal.00075.2018</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00075.2018</ArticleId><ArticleId IdType="pmc">PMC6336994</ArticleId><ArticleId IdType="pubmed">30132346</ArticleId></ArticleIdList></Reference><Reference><Citation>Leerach N, Munesue S, Harashima A, Kimura K, Oshima Y, Kawano S, et al. . RAGE signaling antagonist suppresses mouse macrophage foam cell formation. Biochem Biophys Res Commun. (2021) 555:74&#x2013;80. 10.1016/j.bbrc.2021.03.139</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.03.139</ArticleId><ArticleId IdType="pubmed">33813279</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Conley SM, Li G, Yuan X, Li PL. Rac1 GTPase inhibition blocked podocyte injury and glomerular sclerosis during hyperhomocysteinemia via suppression of nucleotide-binding oligomerization domain-like receptor containing pyrin domain 3 inflammasome activation. Kidney Blood Press Res. (2019) 44:513&#x2013;32. 10.1159/000500457</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000500457</ArticleId><ArticleId IdType="pmc">PMC6800118</ArticleId><ArticleId IdType="pubmed">31266025</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EY, Dryer SE. RAGE and alphaVbeta3-integrin are essential for suPAR signaling in podocytes. Biochim Biophys Acta Mol Basis Dis. (2021) 1867:166186. 10.1016/j.bbadis.2021.166186</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2021.166186</ArticleId><ArticleId IdType="pmc">PMC8328937</ArticleId><ArticleId IdType="pubmed">34166766</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen LJH, Petersen JEV, Eugen-Olsen J. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a biomarker of systemic chronic inflammation. Front Immunol. (2021) 12:780641. 10.3389/fimmu.2021.780641</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.780641</ArticleId><ArticleId IdType="pmc">PMC8674945</ArticleId><ArticleId IdType="pubmed">34925360</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim EY, Hassanzadeh Khayyat N, Dryer SE. Mechanisms underlying modulation of podocyte TRPC6 channels by suPAR: Role of NADPH oxidases and Src family tyrosine kinases. Biochim Biophys Acta Mol Basis Dis. (2018) 1864:3527&#x2013;36. 10.1016/j.bbadis.2018.08.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2018.08.007</ArticleId><ArticleId IdType="pmc">PMC6219472</ArticleId><ArticleId IdType="pubmed">30293571</ArticleId></ArticleIdList></Reference><Reference><Citation>Farmer LK, Rollason R, Whitcomb DJ, Ni L, Goodliff A, Lay AC, et al. . TRPC6 binds to and activates calpain, independent of its channel activity, and regulates podocyte cytoskeleton, cell adhesion, and motility. J Am Soc Nephrol. (2019) 30:1910&#x2013;24. 10.1681/ASN.2018070729</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2018070729</ArticleId><ArticleId IdType="pmc">PMC6779362</ArticleId><ArticleId IdType="pubmed">31416818</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, et al. . AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int. (2004) 66:2137&#x2013;47. 10.1111/j.1523-1755.2004.66004.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.66004.x</ArticleId><ArticleId IdType="pubmed">15569303</ArticleId></ArticleIdList></Reference><Reference><Citation>Glick AD, Jacobson HR, Haralson MA. Mesangial deposition of type I collagen in human glomerulosclerosis. Hum Pathol. (1992) 23:1373&#x2013;9. 10.1016/0046-8177(92)90057-A</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0046-8177(92)90057-A</ArticleId><ArticleId IdType="pubmed">1468774</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HW, Gu MJ, Kim Y, Lee JY, Lee S, Choi IW, et al. . Glyoxal-lysine dimer, an advanced glycation end product, induces oxidative damage and inflammatory response by interacting with RAGE. Antioxidants. (2021) 10:1486. 10.3390/antiox10091486</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10091486</ArticleId><ArticleId IdType="pmc">PMC8470194</ArticleId><ArticleId IdType="pubmed">34573117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HW, Gu MJ, Lee JY, Lee S, Kim Y, Ha SK. Methylglyoxal-lysine dimer, an advanced glycation end product, induces inflammation via interaction with RAGE in mesangial cells. Mol Nutr Food Res. (2021) 65:e2000799. 10.1002/mnfr.202000799</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mnfr.202000799</ArticleId><ArticleId IdType="pubmed">33890707</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression. Horm Metab Res. (2012) 44:891&#x2013;895. 10.1055/s-0032-1321878</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0032-1321878</ArticleId><ArticleId IdType="pubmed">22864903</ArticleId></ArticleIdList></Reference><Reference><Citation>Brings S, Fleming T, Freichel M, Muckenthaler MU, Herzig S, Nawroth PP. Dicarbonyls and advanced glycation end-products in the development of diabetic complications and targets for intervention. Int J Mol Sci. (2017) 18. 10.3390/ijms18050984</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18050984</ArticleId><ArticleId IdType="pmc">PMC5454897</ArticleId><ArticleId IdType="pubmed">28475116</ArticleId></ArticleIdList></Reference><Reference><Citation>Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. (2017) 60:1577&#x2013;85. 10.1007/s00125-017-4342-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-017-4342-z</ArticleId><ArticleId IdType="pmc">PMC5552828</ArticleId><ArticleId IdType="pubmed">28776086</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, An H, Liu T, Qin C, Sesaki H, Guo S, et al. . Metformin improves mitochondrial respiratory activity through activation of AMPK. Cell Rep. (2019) 29:1511&#x2013;23 e1515. 10.1016/j.celrep.2019.09.070</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.09.070</ArticleId><ArticleId IdType="pmc">PMC6866677</ArticleId><ArticleId IdType="pubmed">31693892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EK, Jeong JU, Chang JW, Yang WS, Kim SB, Park SK, et al. . Activation of AMP-activated protein kinase inhibits albumin-induced endoplasmic reticulum stress and apoptosis through inhibition of reactive oxygen species. Nephron Exp Nephrol. (2012) 121:e38&#x2013;48. 10.1159/000342802</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000342802</ArticleId><ArticleId IdType="pubmed">23108012</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang SC, Chan LY, Leung JC, Cheng AS, Lin M, Lan HY, et al. . Differential effects of advanced glycation end-products on renal tubular cell inflammation. Nephrology. (2011) 16:417&#x2013;25. 10.1111/j.1440-1797.2010.01437.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1797.2010.01437.x</ArticleId><ArticleId IdType="pubmed">21143336</ArticleId></ArticleIdList></Reference><Reference><Citation>Canto C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. . AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature. (2009) 458:1056&#x2013;60. 10.1038/nature07813</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature07813</ArticleId><ArticleId IdType="pmc">PMC3616311</ArticleId><ArticleId IdType="pubmed">19262508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J, Zhang Y, Xiao F, Liu Y, Wang J, Gao H, et al. . The peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents NF-kappaB activation in cisplatin nephrotoxicity through the reduction of p65 acetylation via the AMPK-SIRT1/p300 pathway. Biochem Pharmacol. (2016) 101:100&#x2013;11. 10.1016/j.bcp.2015.11.027</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2015.11.027</ArticleId><ArticleId IdType="pubmed">26673543</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J, Schmidt AM. Characterization and functional analysis of the promoter of RAGE. The receptor for advanced glycation end products. J Biol Chem. (1997) 272:16498&#x2013;506. 10.1074/jbc.272.26.16498</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.26.16498</ArticleId><ArticleId IdType="pubmed">9195959</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V, et al. . Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest. (2001) 108:1853&#x2013;63. 10.1172/JCI11951</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI11951</ArticleId><ArticleId IdType="pmc">PMC209461</ArticleId><ArticleId IdType="pubmed">11748269</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JH, Wang W, Huang XR, Oldfield M, Schmidt AM, Cooper ME, et al. . Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol. (2004) 164:1389&#x2013;97. 10.1016/S0002-9440(10)63225-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63225-7</ArticleId><ArticleId IdType="pmc">PMC1615341</ArticleId><ArticleId IdType="pubmed">15039226</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Wu Z, Phan SH. Smad3 mediates transforming growth factor-beta-induced alpha-smooth muscle actin expression. Am J Respir Cell Mol Biol. (2003) 29(Pt. 1):397&#x2013;404. 10.1165/rcmb.2003-0063OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2003-0063OC</ArticleId><ArticleId IdType="pubmed">12702545</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokoyama S, Kawai T, Yamamoto K, Yibin H, Yamamoto H, Kakino A, et al. . RAGE ligands stimulate angiotensin II type I receptor (AT1) via RAGE/AT1 complex on the cell membrane. Sci Rep. (2021) 11:5759. 10.1038/s41598-021-85312-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85312-4</ArticleId><ArticleId IdType="pmc">PMC7952713</ArticleId><ArticleId IdType="pubmed">33707701</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YY, Jiang GT, Chen LJ, Jiang YH, Jiao JD. Formin mDia1 contributes to migration and epithelial-mesenchymal transition of tubular epithelial cells exposed to TGF-beta1. J Cell Biochem. (2019) 121:3861&#x2013;70. 10.1002/jcb.29508</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcb.29508</ArticleId><ArticleId IdType="pubmed">31692057</ArticleId></ArticleIdList></Reference><Reference><Citation>Manigrasso MB, Pan J, Rai V, Zhang J, Reverdatto S, Quadri N, et al. . Small molecule inhibition of ligand-stimulated RAGE-DIAPH1 signal transduction. Sci Rep. (2016) 6:22450. 10.1038/srep22450</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep22450</ArticleId><ArticleId IdType="pmc">PMC4776135</ArticleId><ArticleId IdType="pubmed">26936329</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng M, Liu H, Zhang D, Liu Y, Wang C, Liu F, et al. . HMGB1 enhances the AGE-induced expression of CTGF and TGF-beta via RAGE-dependent signaling in renal tubular epithelial cells. Am J Nephrol. (2015) 41:257&#x2013;266. 10.1159/000381464</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000381464</ArticleId><ArticleId IdType="pubmed">25924590</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran CS, Kopp JB. PD-1 immunobiology in glomerulonephritis and renal cell carcinoma. BMC Nephrol. (2021) 22:80. 10.1186/s12882-021-02257-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-021-02257-6</ArticleId><ArticleId IdType="pmc">PMC7936245</ArticleId><ArticleId IdType="pubmed">33676416</ArticleId></ArticleIdList></Reference><Reference><Citation>Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol Pharm Bull. (2003) 26:753&#x2013;760. 10.1248/bpb.26.753</Citation><ArticleIdList><ArticleId IdType="doi">10.1248/bpb.26.753</ArticleId><ArticleId IdType="pubmed">12808281</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepper RJ, Hamour S, Chavele KM, Todd SK, Rasmussen N, Flint S, et al. . Leukocyte and serum S100A8/S100A9 expression reflects disease activity in ANCA-associated vasculitis and glomerulonephritis. Kidney Int. (2013) 83:1150&#x2013;8. 10.1038/ki.2013.2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2013.2</ArticleId><ArticleId IdType="pmc">PMC3675710</ArticleId><ArticleId IdType="pubmed">23423260</ArticleId></ArticleIdList></Reference><Reference><Citation>Pepper RJ, Wang HH, Rajakaruna GK, Papakrivopoulou E, Vogl T, Pusey CD, et al. . S100A8/A9 (calprotectin) is critical for development of glomerulonephritis and promotes inflammatory leukocyte-renal cell interactions. Am J Pathol. (2015) 185:1264&#x2013;74. 10.1016/j.ajpath.2015.01.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2015.01.015</ArticleId><ArticleId IdType="pmc">PMC4419283</ArticleId><ArticleId IdType="pubmed">25759267</ArticleId></ArticleIdList></Reference><Reference><Citation>Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol. (1998) 160:1427&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">9570563</ArticleId></ArticleIdList></Reference><Reference><Citation>Frommhold D, Kamphues A, Hepper I, Pruenster M, Lukic IK, Socher I, et al. . RAGE and ICAM-1 cooperate in mediating leukocyte recruitment during acute inflammation in vivo. Blood. (2010) 116:841&#x2013;9. 10.1182/blood-2009-09-244293</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-09-244293</ArticleId><ArticleId IdType="pubmed">20407037</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehlermann P, Eggers K, Bierhaus A, Most P, Weichenhan D, Greten J, et al. . Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products. Cardiovasc Diabetol. (2006) 5:6. 10.1186/1475-2840-5-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1475-2840-5-6</ArticleId><ArticleId IdType="pmc">PMC1475836</ArticleId><ArticleId IdType="pubmed">16573830</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong J, Lee J, Lim J, Cho S, An S, Lee M, et al. . Soluble RAGE attenuates AngII-induced endothelial hyperpermeability by disrupting HMGB1-mediated crosstalk between AT1R and RAGE. Exp Mol Med. (2019) 51:1&#x2013;15. 10.1038/s12276-019-0312-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-019-0312-5</ArticleId><ArticleId IdType="pmc">PMC6802637</ArticleId><ArticleId IdType="pubmed">31562296</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma I, Tupe RS, Wallner AK, Kanwar YS. Contribution of myo-inositol oxygenase in AGE:RAGE-mediated renal tubulointerstitial injury in the context of diabetic nephropathy. Am J Physiol Renal Physiol. (2018) 314:F107&#x2013;21. 10.1152/ajprenal.00434.2017</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00434.2017</ArticleId><ArticleId IdType="pmc">PMC5866356</ArticleId><ArticleId IdType="pubmed">28931523</ArticleId></ArticleIdList></Reference><Reference><Citation>Manigrasso MB, Rabbani P, Egana-Gorrono L, Quadri N, Frye L, Zhou B, et al. . Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice. Sci Transl Med. (2021) 13:eabf7084. 10.1126/scitranslmed.abf7084</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf7084</ArticleId><ArticleId IdType="pmc">PMC8669775</ArticleId><ArticleId IdType="pubmed">34818060</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Ma J, Kwan T, Stribos EGD, Messchendorp AL, Loh YW, et al. . Blockade of HMGB1 attenuates diabetic nephropathy in mice. Sci Rep. (2018) 8:8319. 10.1038/s41598-018-26637-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-26637-5</ArticleId><ArticleId IdType="pmc">PMC5974129</ArticleId><ArticleId IdType="pubmed">29844451</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson AM, Gray SP, Jiaze L, Soro-Paavonen A, Wong B, Cooper ME, et al. . Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Diabetes. (2012) 61:2105&#x2013;13. 10.2337/db11-1546</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db11-1546</ArticleId><ArticleId IdType="pmc">PMC3402321</ArticleId><ArticleId IdType="pubmed">22698914</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazumder K, Biswas B, Al Mamun A, Billah H, Abid A, Sarkar KK, et al. . Investigations of AGEs' inhibitory and nephroprotective potential of ursolic acid towards reduction of diabetic complications. J Nat Med. (2022) 76:490&#x2013;503. 10.1007/s11418-021-01602-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11418-021-01602-1</ArticleId><ArticleId IdType="pubmed">35032247</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrypnyk NI, Voziyan P, Yang H, de Caestecker CR, Theberge MC, Drouin M, et al. . Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injury. Am J Physiol Renal Physiol. (2016) 311:F268&#x2013;77. 10.1152/ajprenal.00056.2016</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajprenal.00056.2016</ArticleId><ArticleId IdType="pmc">PMC5008672</ArticleId><ArticleId IdType="pubmed">27194713</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiazza F, Cento AS, Collotta D, Nigro D, Rosa G, Baratta F, et al. . Protective effects of pyridoxamine supplementation in the early stages of diet-induced kidney dysfunction. Biomed Res Int. (2017) 2017:2682861. 10.1155/2017/2682861</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/2682861</ArticleId><ArticleId IdType="pmc">PMC5682048</ArticleId><ArticleId IdType="pubmed">29214163</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu YY, Tang LQ, Wei W. Berberine exerts renoprotective effects by regulating the AGEs-RAGE signaling pathway in mesangial cells during diabetic nephropathy. Mol Cell Endocrinol. (2017) 443:89&#x2013;105. 10.1016/j.mce.2017.01.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2017.01.009</ArticleId><ArticleId IdType="pubmed">28087385</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanajou D, Ghorbani Haghjo A, Argani H, Roshangar L, Rashtchizadeh N, Ahmad SNS, et al. . Reduction of renal tubular injury with a RAGE inhibitor FPS-ZM1, valsartan and their combination in streptozotocin-induced diabetes in the rat. Eur J Pharmacol. (2019) 842:40&#x2013;8. 10.1016/j.ejphar.2018.10.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2018.10.035</ArticleId><ArticleId IdType="pubmed">30393200</ArticleId></ArticleIdList></Reference><Reference><Citation>Parwani K, Patel F, Bhagwat P, Dilip H, Patel D, Thiruvenkatam V, et al. . (2021) Swertiamarin mitigates nephropathy in high-fat diet/streptozotocin-induced diabetic rats by inhibiting the formation of advanced glycation end products. Arch Physiol Biochem. (2021) 16:1&#x2013;19. 10.1080/13813455.2021.1987478</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13813455.2021.1987478</ArticleId><ArticleId IdType="pubmed">34657540</ArticleId></ArticleIdList></Reference><Reference><Citation>Youssef S, Nguyen DT, Soulis T, Panagiotopoulos S, Jerums G, Cooper ME. Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. Kidney Int. (1999) 55:907&#x2013;16. 10.1046/j.1523-1755.1999.055003907.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1523-1755.1999.055003907.x</ArticleId><ArticleId IdType="pubmed">10027927</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly DJ, Gilbert RE, Cox AJ, Soulis T, Jerums G, Cooper ME. Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. J Am Soc Nephrol. (2001) 12:2098&#x2013;107. 10.1681/ASN.V12102098</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.V12102098</ArticleId><ArticleId IdType="pubmed">11562408</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Zhang R, Chen J, Shi M, Li W, Zhang X. High mobility group box1 inhibitor glycyrrhizic acid attenuates kidney injury in streptozotocin-induced diabetic rats. Kidney Blood Press Res. (2017) 42:894&#x2013;904. 10.1159/000485045</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000485045</ArticleId><ArticleId IdType="pubmed">29241180</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Gu W, Lu H, Liu C, Yu B, Xu H, et al. . Soluble receptor for advanced glycation end product ameliorates chronic intermittent hypoxia induced renal injury, inflammation, and apoptosis via P38/JNK signaling pathways. Oxid Med Cell Longev. (2016) 2016:1015390. 10.1155/2016/1015390</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/1015390</ArticleId><ArticleId IdType="pmc">PMC5027322</ArticleId><ArticleId IdType="pubmed">27688824</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed JC, Preston-Hurlburt P, Philbrick W, Betancur G, Korah M, Lucas C, et al. . The receptor for advanced glycation endproducts (RAGE) modulates T cell signaling. PLoS ONE. (2020) 15:e0236921. 10.1371/journal.pone.0236921</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0236921</ArticleId><ArticleId IdType="pmc">PMC7521722</ArticleId><ArticleId IdType="pubmed">32986722</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatila TA, Benamar M, Chen Q, Chou J, Jule A, Boudra R, et al. . (2022) Notch1-CD22-dependent immune dysregulation in the SARS-CoV2-associated multisystem inflammatory syndrome in children. Preprint. Res Sq. 10.21203/rs.3.rs-1054453/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1054453/v1</ArticleId><ArticleId IdType="pmc">PMC9016654</ArticleId><ArticleId IdType="pubmed">35441180</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartolome A, Liang J, Wang P, Ho DD, Pajvani UB. Angiotensin converting enzyme 2 is a novel target of the gamma-secretase complex. Sci Rep. (2021) 11:9803. 10.1038/s41598-021-89379-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-89379-x</ArticleId><ArticleId IdType="pmc">PMC8105332</ArticleId><ArticleId IdType="pubmed">33963249</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran CS, Rivera DR, Kopp JB. COVID-19 usurps host regulatory networks. Front Pharmacol. (2020) 11:1278. 10.3389/fphar.2020.01278</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.01278</ArticleId><ArticleId IdType="pmc">PMC7456869</ArticleId><ArticleId IdType="pubmed">32922297</ArticleId></ArticleIdList></Reference><Reference><Citation>Batlle D, Wysocki J, Soler MJ, Ranganath K. Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney Int. (2012) 81:520&#x2013;528. 10.1038/ki.2011.381</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2011.381</ArticleId><ArticleId IdType="pubmed">22113528</ArticleId></ArticleIdList></Reference><Reference><Citation>Tikellis C, Bialkowski K, Pete J, Sheehy K, Su Q, Johnston C, et al. . ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes. (2008) 57:1018&#x2013;25. 10.2337/db07-1212</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/db07-1212</ArticleId><ArticleId IdType="pubmed">18235039</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, et al. . ACE Inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials. Drugs. (2020) 80:797&#x2013;811. 10.1007/s40265-020-01290-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-020-01290-3</ArticleId><ArticleId IdType="pmc">PMC7242277</ArticleId><ArticleId IdType="pubmed">32333236</ArticleId></ArticleIdList></Reference><Reference><Citation>Chrysanthopoulou A, Gkaliagkousi E, Lazaridis A, Arelaki S, Pateinakis P, Ntinopoulou M, et al. . Angiotensin II triggers release of neutrophil extracellular traps, linking thromboinflammation with essential hypertension. JCI Insight. (2021) 6:e148668. 10.1172/jci.insight.148668</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.148668</ArticleId><ArticleId IdType="pmc">PMC8492353</ArticleId><ArticleId IdType="pubmed">34324440</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, Fogo AB, et al. . Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis. Arterioscler Thromb Vasc Biol. (2011) 31:2856&#x2013;64. 10.1161/ATVBAHA.111.237198</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.111.237198</ArticleId><ArticleId IdType="pmc">PMC3227118</ArticleId><ArticleId IdType="pubmed">21979434</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessop F, Schwarz B, Scott D, Roberts LM, Bohrnsen E, Hoidal JR, et al. . Impairing RAGE signaling promotes survival and limits disease pathogenesis following SARS-CoV-2 infection in mice. JCI Insight. (2022) 7:e155896. 10.1172/jci.insight.155896</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.155896</ArticleId><ArticleId IdType="pmc">PMC8855831</ArticleId><ArticleId IdType="pubmed">35076028</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapandji N, Yvin E, Devriese M, de Margerie-Mellon C, Moratelli G, Lemiale V, et al. . Importance of lung epithelial injury in COVID-19-associated acute respiratory distress syndrome: value of plasma soluble receptor for advanced glycation end-products. Am J Respir Crit Care Med. (2021) 204:359&#x2013;62. 10.1164/rccm.202104-1070LE</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202104-1070LE</ArticleId><ArticleId IdType="pmc">PMC8513587</ArticleId><ArticleId IdType="pubmed">34033529</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim A, Radujkovic A, Weigand MA, Merle U. Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COVID-19 disease severity and indicator of the need for mechanical ventilation, ARDS and mortality. Ann Intensive Care. (2021) 11:50. 10.1186/s13613-021-00836-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-021-00836-2</ArticleId><ArticleId IdType="pmc">PMC7983090</ArticleId><ArticleId IdType="pubmed">33751264</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumas G, Kapandji N, Azoulay E, Constantin JM. Reply to Jain: high circulating plasma soluble receptor for advanced glycation end-products in early COVID-19-associated acute respiratory distress syndrome: pathophysiological significance? Am J Respir Crit Care Med. (2022) 205:256&#x2013;57. 10.1164/rccm.202108-1969LE</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202108-1969LE</ArticleId><ArticleId IdType="pmc">PMC8787249</ArticleId><ArticleId IdType="pubmed">34727509</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalcin Kehribar D, Cihangiroglu M, Sehmen E, Avci B, Capraz A, Yildirim Bilgin A, et al. . The receptor for advanced glycation end product (RAGE) pathway in COVID-19. Biomarkers. (2021) 26:114&#x2013;8. 10.1080/1354750X.2020.1861099</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1354750X.2020.1861099</ArticleId><ArticleId IdType="pmc">PMC7814566</ArticleId><ArticleId IdType="pubmed">33284049</ArticleId></ArticleIdList></Reference><Reference><Citation>Dozio E, Sitzia C, Pistelli L, Cardani R, Rigolini R, Ranucci M, et al. . Soluble receptor for advanced glycation end products and its forms in COVID-19 patients with and without diabetes mellitus: a pilot study on their role as disease biomarkers. J Clin Med. (2020) 9:3785. 10.3390/jcm9113785</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9113785</ArticleId><ArticleId IdType="pmc">PMC7700384</ArticleId><ArticleId IdType="pubmed">33238596</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Ma L, Nicholson LF, Black PN. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir Med. (2011) 105:329&#x2013;36. 10.1016/j.rmed.2010.11.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2010.11.001</ArticleId><ArticleId IdType="pubmed">21112201</ArticleId></ArticleIdList></Reference><Reference><Citation>Rungratanawanich W, Qu Y, Wang X, Essa MM, Song BJ. Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury. Exp Mol Med. (2021) 53:168&#x2013;88. 10.1038/s12276-021-00561-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-021-00561-7</ArticleId><ArticleId IdType="pmc">PMC8080618</ArticleId><ArticleId IdType="pubmed">33568752</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Zhou C, Huang M, Tang C, Liu X, Yue Y, et al. . Glyoxalase system: a systematic review of its biological activity, related-diseases, screening methods and small molecule regulators. Biomed Pharmacother. (2020) 131:110663. 10.1016/j.biopha.2020.110663</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2020.110663</ArticleId><ArticleId IdType="pubmed">32858501</ArticleId></ArticleIdList></Reference><Reference><Citation>Castilla J, Guevara M, Miqueleiz A, Baigorria F, Ibero-Esparza C, Navascues A, et al. . Risk factors of infection, hospitalization and death from SARS-CoV-2: a population-based cohort study. J Clin Med. (2021) 10:2608. 10.3390/jcm10122608</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10122608</ArticleId><ArticleId IdType="pmc">PMC8231921</ArticleId><ArticleId IdType="pubmed">34199198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee AC, Li WT, Apostol L, Ma J, Taub PR, Chang EY, et al. . Cardiovascular, cerebrovascular, and renal co-morbidities in COVID-19 patients: a systematic-review and meta-analysis. Comput Struct Biotechnol J. (2021) 19:3755&#x2013;64. 10.1016/j.csbj.2021.06.038</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2021.06.038</ArticleId><ArticleId IdType="pmc">PMC8238636</ArticleId><ArticleId IdType="pubmed">34221254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu L, Baylan U, van der Leeden B, Schurink B, Roos E, Schalkwijk CG, et al. . Cardiac inflammation and microvascular procoagulant changes are decreased in second wave compared to first wave deceased COVID-19 patients. Int J Cardiol. (2022) 349:157&#x2013;65. 10.1016/j.ijcard.2021.11.079</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2021.11.079</ArticleId><ArticleId IdType="pmc">PMC8641429</ArticleId><ArticleId IdType="pubmed">34871622</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Hasse S, Zhao C, Bourgoin SG. Targeting the autotaxin - lysophosphatidic acid receptor axis in cardiovascular diseases. Biochem Pharmacol. (2019) 164:74&#x2013;81. 10.1016/j.bcp.2019.03.035</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2019.03.035</ArticleId><ArticleId IdType="pubmed">30928673</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew D, Torres RM. Lysophosphatidic acid is an inflammatory lipid exploited by cancers for immune evasion via mechanisms similar and distinct from CTLA-4 and PD-1. Front Immunol. (2020) 11:531910. 10.3389/fimmu.2020.531910</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.531910</ArticleId><ArticleId IdType="pmc">PMC7873449</ArticleId><ArticleId IdType="pubmed">33584637</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalczyk A, Dolegowska B, Heryc R, Chlubek D, Safranow K. Associations between plasma lysophospholipids concentrations, chronic kidney disease and the type of renal replacement therapy. Lipids Health Dis. (2019) 18:85. 10.1186/s12944-019-1040-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12944-019-1040-5</ArticleId><ArticleId IdType="pmc">PMC6449907</ArticleId><ArticleId IdType="pubmed">30947711</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikitopoulou I, Fanidis D, Ntatsoulis K, Moulos P, Mpekoulis G, Evangelidou M, et al. . Increased autotaxin levels in severe COVID-19, correlating with IL-6 levels, endothelial dysfunction biomarkers, and impaired functions of dendritic cells. Int J Mol Sci. (2021) 22:10006. 10.3390/ijms221810006</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms221810006</ArticleId><ArticleId IdType="pmc">PMC8469279</ArticleId><ArticleId IdType="pubmed">34576169</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamers C, Pluss CJ, Ricklin D. The promiscuous profile of complement receptor 3 in ligand binding, immune modulation, and pathophysiology. Front Immunol. (2021) 12:662164. 10.3389/fimmu.2021.662164</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.662164</ArticleId><ArticleId IdType="pmc">PMC8118671</ArticleId><ArticleId IdType="pubmed">33995387</ArticleId></ArticleIdList></Reference><Reference><Citation>Peter K, Schwarz M, Conradt C, Nordt T, Moser M, Kubler W, et al. . Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18). Circulation. (1999) 100:1533&#x2013;9. 10.1161/01.CIR.100.14.1533</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.100.14.1533</ArticleId><ArticleId IdType="pubmed">10510057</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouhiainen A, Nykanen NP, Kuja-Panula J, Vanttola P, Huttunen HJ, Rauvala H. Inhibition of homophilic interactions and ligand binding of the receptor for advanced glycation end products by heparin and heparin-related carbohydrate structures. Medicines. (2018) 5:79. 10.3390/medicines5030079</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medicines5030079</ArticleId><ArticleId IdType="pmc">PMC6165534</ArticleId><ArticleId IdType="pubmed">30061484</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling Y, Yang ZY, Yin T, Li L, Yuan WW, Wu HS, et al. . Heparin changes the conformation of high-mobility group protein 1 and decreases its affinity toward receptor for advanced glycation endproducts in vitro. Int Immunopharmacol. (2011) 11:187&#x2013;93. 10.1016/j.intimp.2010.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2010.11.014</ArticleId><ArticleId IdType="pubmed">21095260</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E, et al. . A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J. (2007) 26:1129&#x2013;39. 10.1038/sj.emboj.7601552</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.emboj.7601552</ArticleId><ArticleId IdType="pmc">PMC1852832</ArticleId><ArticleId IdType="pubmed">17268551</ArticleId></ArticleIdList></Reference><Reference><Citation>Dal Canton A. Adhesion molecules in renal disease. Kidney Int. (1995) 48:1687&#x2013;96. 10.1038/ki.1995.466</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1995.466</ArticleId><ArticleId IdType="pubmed">8587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagashima S, Mendes MC, Camargo Martins AP, Borges NH, Godoy TM, Miggiolaro A, et al. . Endothelial dysfunction and thrombosis in patients with COVID-19-brief report. Arterioscler Thromb Vasc Biol. (2020) 40:2404&#x2013;7. 10.1161/ATVBAHA.120.314860</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.314860</ArticleId><ArticleId IdType="pmc">PMC7505138</ArticleId><ArticleId IdType="pubmed">32762443</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirahashi J, Hishikawa K, Kaname S, Tsuboi N, Wang Y, Simon DI, et al. . Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury. Circulation. (2009) 120:1255&#x2013;65. 10.1161/CIRCULATIONAHA.109.873695</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.873695</ArticleId><ArticleId IdType="pmc">PMC2780001</ArticleId><ArticleId IdType="pubmed">19752320</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta R, Gant VA, Williams B, Enver T. Increased complement receptor-3 levels in monocytes and granulocytes distinguish COVID-19 patients with pneumonia from those with mild symptoms. Int J Infect Dis. (2020) 99:381&#x2013;5. 10.1016/j.ijid.2020.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7836814</ArticleId><ArticleId IdType="pubmed">32771640</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattar Z, Lora A, Jundi B, Railwah C, Geraghty P. The S100 protein family as players and therapeutic targets in pulmonary diseases. Pulm Med. (2021) 2021:5488591. 10.1155/2021/5488591</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/5488591</ArticleId><ArticleId IdType="pmc">PMC8214497</ArticleId><ArticleId IdType="pubmed">34239729</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalejaiye TD, Bhattacharya R, Burt MA, Travieso T, Okafor AE, Mou X, et al. . SARS-CoV-2 employ BSG/CD147 and ACE2 receptors to directly infect human induced pluripotent stem cell-derived kidney podocytes. Front Cell Dev Biol. (2022) 10:855340. 10.3389/fcell.2022.855340</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2022.855340</ArticleId><ArticleId IdType="pmc">PMC9065256</ArticleId><ArticleId IdType="pubmed">35517495</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Kuang M, Li J, Zhu L, Jia Z, Guo X, et al. . SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res. (2021) 31:818&#x2013;20. 10.1038/s41422-021-00495-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-021-00495-9</ArticleId><ArticleId IdType="pmc">PMC7975240</ArticleId><ArticleId IdType="pubmed">33742149</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolakopoulou Z, Hector LR, Creagh-Brown BC, Evans TW, Quinlan GJ, Burke-Gaffney A. Plasma S100A8/A9 heterodimer is an early prognostic marker of acute kidney injury associated with cardiac surgery. Biomark Med. (2019) 13:205&#x2013;18. 10.2217/bmm-2018-0238</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2018-0238</ArticleId><ArticleId IdType="pubmed">30810341</ArticleId></ArticleIdList></Reference><Reference><Citation>Tammaro A, Florquin S, Brok M, Claessen N, Butter LM, Teske GJD, et al. . S100A8/A9 promotes parenchymal damage and renal fibrosis in obstructive nephropathy. Clin Exp Immunol. (2018) 193:361&#x2013;75. 10.1111/cei.13154</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13154</ArticleId><ArticleId IdType="pmc">PMC6150262</ArticleId><ArticleId IdType="pubmed">29746703</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Long X, Xu Q, Tan J, Wang G, Cao Y, et al. . Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cell Mol Immunol. (2020) 17:992&#x2013;4. 10.1038/s41423-020-0492-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0492-x</ArticleId><ArticleId IdType="pmc">PMC7332851</ArticleId><ArticleId IdType="pubmed">32620787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bengtsson AA, Sturfelt G, Lood C, Ronnblom L, van Vollenhoven RF, Axelsson B, et al. . Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus. Arthritis Rheum. (2012) 64:1579&#x2013;88. 10.1002/art.33493</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.33493</ArticleId><ArticleId IdType="pubmed">22131101</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Q, Zhao Y, Li J, Liu J, Yang X, Guo X, et al. . Induction of alarmin S100A8/A9 mediates activation of aberrant neutrophils in the pathogenesis of COVID-19. Cell Host Microbe. (2021) 29:222&#x2013;35 e224. 10.1016/j.chom.2020.12.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.12.016</ArticleId><ArticleId IdType="pmc">PMC7762710</ArticleId><ArticleId IdType="pubmed">33388094</ArticleId></ArticleIdList></Reference><Reference><Citation>Aceti A, Margarucci LM, Scaramucci E, Orsini M, Salerno G, Di Sante G, et al. . Serum S100B protein as a marker of severity in Covid-19 patients. Sci Rep. (2020) 10:18665. 10.1038/s41598-020-75618-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-75618-0</ArticleId><ArticleId IdType="pmc">PMC7596559</ArticleId><ArticleId IdType="pubmed">33122776</ArticleId></ArticleIdList></Reference><Reference><Citation>Park BS, Lee HW, Lee YJ, Park S, Kim YW, Kim SE, et al. . Serum S100B represents a biomarker for cognitive impairment in patients with end-stage renal disease. Clin Neurol Neurosurg. (2020) 195:105902. 10.1016/j.clineuro.2020.105902</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clineuro.2020.105902</ArticleId><ArticleId IdType="pubmed">32442806</ArticleId></ArticleIdList></Reference><Reference><Citation>Mete E, Sabirli R, Goren T, Turkcuer I, Kurt O, Koseler A. Association between S100b levels and COVID-19 pneumonia: a case control study. In Vivo. (2021) 35:2923&#x2013;8. 10.21873/invivo.12583</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/invivo.12583</ArticleId><ArticleId IdType="pmc">PMC8408717</ArticleId><ArticleId IdType="pubmed">34410988</ArticleId></ArticleIdList></Reference><Reference><Citation>Inyushin M, Zayas-Santiago A, Rojas L, Kucheryavykh L. On the role of platelet-generated amyloid beta peptides in certain amyloidosis health complications. Front Immunol. (2020) 11:571083. 10.3389/fimmu.2020.571083</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.571083</ArticleId><ArticleId IdType="pmc">PMC7567018</ArticleId><ArticleId IdType="pubmed">33123145</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian DY, Cheng Y, Zhuang ZQ, He CY, Pan QG, Tang MZ, et al. . Physiological clearance of amyloid-beta by the kidney and its therapeutic potential for Alzheimer's disease. Mol Psychiatry. (2021) 26:6074&#x2013;82. 10.1038/s41380-021-01073-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01073-6</ArticleId><ArticleId IdType="pubmed">33828237</ArticleId></ArticleIdList></Reference><Reference><Citation>Idrees D, Kumar V. SARS-CoV-2 spike protein interactions with amyloidogenic proteins: potential clues to neurodegeneration. Biochem Biophys Res Commun. (2021) 554:94&#x2013;8. 10.1016/j.bbrc.2021.03.100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2021.03.100</ArticleId><ArticleId IdType="pmc">PMC7988450</ArticleId><ArticleId IdType="pubmed">33789211</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu JT, Tien CF, Yu GY, Shen S, Lee YH, Hsu PC, et al. . The effects of Abeta1-42 binding to the SARS-CoV-2 spike protein S1 subunit and angiotensin-converting enzyme 2. Int J Mol Sci. (2021) 22:8226. 10.3390/ijms22158226</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22158226</ArticleId><ArticleId IdType="pmc">PMC8347908</ArticleId><ArticleId IdType="pubmed">34360989</ArticleId></ArticleIdList></Reference><Reference><Citation>Huttunen HJ, Rauvala H. Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J Intern Med. (2004) 255:351&#x2013;66. 10.1111/j.1365-2796.2003.01301.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2796.2003.01301.x</ArticleId><ArticleId IdType="pubmed">14871459</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Guan X, Zuo X, Wang J, Yin W. The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases. Acta Pharm Sin B. (2016) 6:183&#x2013;8. 10.1016/j.apsb.2016.02.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2016.02.004</ArticleId><ArticleId IdType="pmc">PMC4856949</ArticleId><ArticleId IdType="pubmed">27175328</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R, Huang Y, Quan J, Liu J, Wang H, Billiar TR, et al. . HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon. (2020) 6:e05672. 10.1016/j.heliyon.2020.e05672</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2020.e05672</ArticleId><ArticleId IdType="pmc">PMC7720697</ArticleId><ArticleId IdType="pubmed">33313438</ArticleId></ArticleIdList></Reference><Reference><Citation>Sivakorn C, Dechsanga J, Jamjumrus L, Boonnak K, Schultz MJ, Dondorp AM, et al. . High mobility group box 1 and interleukin 6 at intensive care unit admission as biomarkers in critically ill COVID-19 patients. Am J Trop Med Hyg. (2021) 105:73&#x2013;80. 10.4269/ajtmh.21-0165</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.21-0165</ArticleId><ArticleId IdType="pmc">PMC8274790</ArticleId><ArticleId IdType="pubmed">33939645</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Liu H, Zeng Q, Imperato GH, Addorisio ME, Li J, et al. . Inhibition of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-HMGB1 antibodies, and cholinergic agonists suppresses inflammation. Mol Med. (2019) 25:13. 10.1186/s10020-019-0081-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10020-019-0081-6</ArticleId><ArticleId IdType="pmc">PMC6460792</ArticleId><ArticleId IdType="pubmed">30975096</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Xiang A, Peng T, Doran AC, Tracey KJ, Barnes BJ, et al. . HMGB1-C1q complexes regulate macrophage function by switching between leukotriene and specialized proresolving mediator biosynthesis. Proc Natl Acad Sci U S A. (2019) 116:23254&#x2013;63. 10.1073/pnas.1907490116</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1907490116</ArticleId><ArticleId IdType="pmc">PMC6859319</ArticleId><ArticleId IdType="pubmed">31570601</ArticleId></ArticleIdList></Reference><Reference><Citation>Savitt AG, Manimala S, White T, Fandaros M, Yin W, Duan H, et al. . SARS-CoV-2 exacerbates covid-19 pathology through activation of the complement and kinin systems. Front Immunol. (2021) 12:767347. 10.3389/fimmu.2021.767347</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.767347</ArticleId><ArticleId IdType="pmc">PMC8602850</ArticleId><ArticleId IdType="pubmed">34804054</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfister F, Vonbrunn E, Ries T, Jack HM, Uberla K, Lochnit G, et al. . Complement activation in kidneys of patients with COVID-19. Front Immunol. (2020) 11:594849. 10.3389/fimmu.2020.594849</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.594849</ArticleId><ArticleId IdType="pmc">PMC7878379</ArticleId><ArticleId IdType="pubmed">33584662</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamaly S, Tsokos MG, Bhargava R, Brook OR, Hecht JL, Abdi R, et al. . Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19. Clin Immunol. (2021) 229:108795. 10.1016/j.clim.2021.108795</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108795</ArticleId><ArticleId IdType="pmc">PMC8270746</ArticleId><ArticleId IdType="pubmed">34252574</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross GD. Role of the lectin domain of Mac-1/CR3 (CD11b/CD18) in regulating intercellular adhesion. Immunol Res. (2002) 25:219&#x2013;27. 10.1385/IR:25:3:219</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/IR:25:3:219</ArticleId><ArticleId IdType="pubmed">12018461</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, et al. . The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. (2003) 198:1507&#x2013;15. 10.1084/jem.20030800</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20030800</ArticleId><ArticleId IdType="pmc">PMC2194124</ArticleId><ArticleId IdType="pubmed">14623906</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansrivijit P, Chen YJ, Lnu K, Trongtorsak A, Puthenpura MM, Thongprayoon C, et al. . Prediction of mortality among patients with chronic kidney disease: a systematic review. World J Nephrol. (2021) 10:59&#x2013;75. 10.5527/wjn.v10.i4.59</Citation><ArticleIdList><ArticleId IdType="doi">10.5527/wjn.v10.i4.59</ArticleId><ArticleId IdType="pmc">PMC8353601</ArticleId><ArticleId IdType="pubmed">34430385</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayek SS, Leaf DE, Samman Tahhan A, Raad M, Sharma S, Waikar SS, et al. . Soluble urokinase receptor and acute kidney injury. N Engl J Med. (2020) 382:416&#x2013;26. 10.1056/NEJMoa1911481</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1911481</ArticleId><ArticleId IdType="pmc">PMC7065830</ArticleId><ArticleId IdType="pubmed">31995687</ArticleId></ArticleIdList></Reference><Reference><Citation>Enocsson H, Idoff C, Gustafsson A, Govender M, Hopkins F, Larsson M, et al. . Soluble Urokinase Plasminogen Activator Receptor (suPAR) independently predicts severity and length of hospitalisation in patients with COVID-19. Front Med. (2021) 8:791716. 10.3389/fmed.2021.791716</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.791716</ArticleId><ArticleId IdType="pmc">PMC8674575</ArticleId><ArticleId IdType="pubmed">34926532</ArticleId></ArticleIdList></Reference><Reference><Citation>Azam TU, Shadid HR, Blakely P, O'Hayer P, Berlin H, Pan M, et al. . Soluble Urokinase Receptor (SuPAR) in COVID-19-related AKI. J Am Soc Nephrol. (2020) 31:2725&#x2013;35. 10.1681/ASN.2020060829</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2020060829</ArticleId><ArticleId IdType="pmc">PMC7608953</ArticleId><ArticleId IdType="pubmed">32963090</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>